Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVA-BN filovirus vaccine - Bavarian Nordic

Next Previous
Drug Profile

MVA-BN filovirus vaccine - Bavarian Nordic

Alternative Names: Ebola Marburg virus vaccine - Bavarian Nordic; Marburg Ebola virus vaccine - Bavarian Nordic; Modified Vaccinia Ankara Bavarian Nordic Marburg Ebola vaccine; MVA-BN Filo; MVA-BN-EBOV-MARV; MVA-BN-MARV-EBOV; MVA-BN®Filo vaccine; MVABEA

Latest Information Update: 29 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bavarian Nordic
  • Developer Bavarian Nordic; Crucell; Janssen Vaccines and Prevention B.V; London School of Hygiene & Tropical Medicine; University of Maryland, Baltimore; Wellcome Trust
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ebola virus infections
  • Phase II Marburg virus disease

Most Recent Events

  • 13 Dec 2023 Janssen terminates a phase III trial for Ebola virus infections (In adolescents, In children, In the elderly, Prevention, In adults, In infants, In neonates) in USA, Burkina Faso, France, Kenya, Tanzania, Uganda, and the UK due to the pandemic with only one participant in follow up, as the impact on the safety was determined to be negligible (NCT02661464)
  • 22 Sep 2022 Janssen completes a phase II trial in Ebola virus infections (Prevention, In infants) in Guinea and Sierra Leone (NCT03929757)
  • 19 Sep 2022 London School of Hygiene and Tropical Medicine in collaboration with University of Sierra Leone, Janssen Vaccines & Prevention initiates enrolment in a phase II clinical trial for Ebola virus infections (Prevention, In children, In adolescents, In adults) in Sierra Leone (IM) (NCT05284097)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top